Cell La Vie Blog

If you’re caring for a parent or spouse with Alzheimer’s, you’ve probably read everything you can find about lecanemab, donanemab, and the new generation of monoclonal antibody drugs that hit the news in 2024-2025. You may have also read about MSC therapy for Alzheimer’s — and you may be wondering whether it’s a real option for your family, or just another overhyped stem cell claim. The honest answer in 2026: MSC therapy for Alzheimer’s is a different approach than the antibody drugs, it’s at an earlier stage of evidence, and it has a specific profile of patients who benefit most. This is a patient-friendly guide to what the 2026 data actually says.

Companion post: post 676 (June 2026) covers the technical/translational MSC-Alzheimer’s research in detail. This post is the patient-facing version with the practical questions families actually ask.

What Alzheimer’s disease actually is, in 2026

Alzheimer’s is a neurodegenerative disease that affects memory, thinking, and behavior. The 2026 Molecular Neurobiology MSC-exosome review (Zhang et al., DOI 10.1007/s12035-026-06002-8) summarized the current understanding: Alzheimer’s is characterized by accumulation of amyloid-beta plaques outside neurons, neurofibrillary tangles of hyperphosphorylated tau inside neurons, chronic neuroinflammation, synaptic loss, and progressive neuron death. The disease typically starts with mild memory loss 10-20 years before clinical diagnosis, progresses through mild cognitive impairment (MCI), and eventually reaches the dementia stage where independent function is lost.

The 2026 J Prev Alzheimers Dis paper on subtle cognitive decline biomarkers (López-Martos et al., DOI 10.1016/j.tjpad.2026.100612) is one of the clearest pictures we have of the preclinical phase — measurable changes in CSF and plasma biomarkers, subtle cognitive decline detectable on neuropsychological testing, all before clinical diagnosis. The 2026 Nature Genetics AD GWAS (EADB consortium, DOI 10.1038/s41588-026-02583-1) added new risk loci to the 70+ known Alzheimer’s risk genes.

What this means practically: by the time someone has clinical Alzheimer’s dementia, the disease has been progressing for 10-20 years. Most of the brain damage is already done. This is why prevention and early intervention are so important, and why treatment response is so much better in early disease than late disease.

What the 2026 antibody drugs do (and don’t do)

The 2024-2026 antibody drugs — lecanemab (Leqembi), donanemab (Kisunla), and the second-generation antibodies in late-stage trials — work by clearing amyloid-beta from the brain. The 2026 Frontiers in Molecular Biosciences paper on APOE3-Christchurch variant (Rodriguez Martinez et al., DOI 10.3389/fmolb.2026.1778856) provided fascinating new mechanism data: this naturally occurring APOE variant enhances neurovascular support functions of iPSC-derived mesenchymal stromal cells, which may explain the protective effect observed in a Colombian woman who was homozygous for APOE3-Christchurch and was cognitively normal at age 70 despite carrying the autosomal-dominant Paisa presenilin-1 mutation.

What the antibody drugs do in 2026:

• Modestly slow cognitive and functional decline — about 25-35% slowing on the CDR-SB scale over 18 months in the lecanemab Phase 3 CLARITY-AD trial
• Significantly reduce amyloid plaque burden on PET imaging (most patients reach amyloid-negative status by 18 months)
• Modestly slow tau accumulation on tau PET
• Carry real risk: ARIA (amyloid-related imaging abnormalities) with edema or microhemorrhages occur in 21-36% of patients on lecanemab, with 0.5-1% being serious enough to require hospitalization. Most ARIA cases are asymptomatic and detected only on monitoring MRI.

What the antibody drugs don’t do in 2026:

• They don’t reverse established cognitive decline. Patients on lecanemab for 18 months are still declining — just more slowly than placebo.
• They don’t address neuroinflammation, which is increasingly understood as a major driver of progression
• They don’t address tau pathology directly, which correlates better with cognitive symptoms than amyloid burden
• They don’t restore lost neurons or synapses
• They don’t work well in late-stage disease

The honest 2026 picture: lecanemab and donanemab are real advances, they’re the first disease-modifying drugs for Alzheimer’s, and they have a clear place in early-stage disease. But they’re not cures, they have meaningful safety risks, and many patients and families reasonably decide the trade-off isn’t right for them.

What MSC therapy does differently

MSC therapy for Alzheimer’s takes a fundamentally different approach than the antibody drugs. The 2026 Molecular Neurobiology review (Zhang et al., DOI 10.1007/s12035-026-06002-8) and the 2026 Pharmaceutics review on MSC-EV preconditioning (Costanzi et al., DOI 10.3390/pharmaceutics18060730) covered the mechanisms:

• Anti-neuroinflammation. MSCs and MSC-EVs shift microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, reducing IL-1β, IL-6, and TNF-α in the brain. This addresses the chronic neuroinflammation that the antibody drugs don’t touch.
• Tau modulation. MSC-EVs reduce tau hyperphosphorylation through multiple kinase pathways (GSK-3β, CDK5). The antibody drugs don’t do this.
• Amyloid clearance via phagocytosis activation. MSCs activate microglial phagocytosis of amyloid plaques, which is a different mechanism than the antibody-drug direct binding.
• Synaptic protection. MSC-EVs promote synaptogenesis and protect existing synapses from inflammatory damage.
• Mitochondrial transfer. MSCs can transfer healthy mitochondria to damaged neurons via tunneling nanotubes, restoring their energy production.
• Neurotrophic factor delivery. MSCs secrete BDNF, GDNF, and NGF locally, supporting neuron survival.

The 2026 Clinical Anatomy histological review (Fikry et al., DOI 10.1002/ca.70147) confirmed that MSC therapies in neurodegenerative disorders show measurable improvements in neuronal density, synaptic markers, and reduced gliosis in preclinical models and early human studies.

What this means: MSC therapy doesn’t compete with lecanemab. The two approaches are addressing different parts of the Alzheimer’s problem. In theory, they could be combined. In practice, no large trial has tested the combination yet, and most patients receive one or the other.

How MSC therapy for Alzheimer’s works in practice

At our clinic in Bangkok and at centers running the 2026 trials (NCT06775964, NCT06781333, NCT07512362, NCT07367815, NCT06607900), the protocols are converging on a similar structure. The 2024-2026 Alzheimer’s MSC trial portfolio includes:

• NCT06775964 (Stem cell therapy for early AD): Phase 1/2, recruiting since March 2026. UC-MSC delivered by intravenous infusion in early AD. Co-primary endpoints are safety and 12-month cognitive change (ADAS-Cog, MMSE).
• NCT06781333 (hMSC for AD behavioral problems): Phase 2, recruiting since April 2025. UC-MSC delivered by IV in AD patients with significant behavioral symptoms. Primary endpoint is NPI (Neuropsychiatric Inventory) change.
• NCT07512362 (hMSC + monoclonal antibodies in mild cognitive impairment): Phase 2, recruiting since May 2026. This is the first trial combining MSC therapy with the antibody drugs — patients on lecanemab or donanemab receive MSC add-on therapy.
• NCT07367815 (Allogeneic adipose-derived stem cells in AD): Phase 1/2, recruiting since May 2026. Allogeneic ADSC delivered IV.
• NCT06607900 (hUC-MSC-sEV-001 nasal drops): Phase 1, not yet recruiting. MSC-derived small EV delivered as nasal drops — bypasses the IV route, delivers EVs directly to the brain via the olfactory nerve pathway. The 2026 Front Cell Dev Biol review (Li et al., DOI 10.3389/fcell.2026.1839015) framed nasal EV delivery as an emerging direction for CNS cell therapy.
• NCT04482413 (AstroStem): Phase 2, status unknown since 2023. Korean trial of autologous ADSC in AD.

What the treatment course looks like in practice at our clinic and the trial sites:

• Pre-treatment assessment: Comprehensive cognitive testing (MMSE, MoCA, ADAS-Cog), MRI brain, amyloid and tau PET if available, CSF biomarker panel (Aβ42/40 ratio, p-tau181, total tau), APOE genotyping, routine labs. The 2026 J Prev Alzheimers Dis subtle cognitive decline paper (López-Martos et al.) shows that the most informative baseline includes both neuropsychological and biomarker data.
• Treatment course: Most protocols use 4-6 IV infusions over the first 6-12 months, spaced 4-8 weeks apart. The IV route is the standard; the nasal EV delivery (NCT06607900) is the next generation. Doses range from 50-200 million cells per infusion in the active trials.
• Concurrent therapy: Patients are continued on their standard AD medications (donepezil, memantine) and may be on lecanemab or donanemab. The 2026 combination trial (NCT07512362) is the first formal test of MSC + antibody drug.
• Outcome tracking: Repeat cognitive testing at 3, 6, 12 months. MRI brain at 6 and 12 months. Optional repeat CSF biomarkers. Family-reported functional changes (caregiver input is critical in AD trials).

What this costs in 2026: at our Bangkok clinic, a full MSC-Alzheimer’s protocol (6 infusions plus assessments) runs USD 15,000-25,000. Comparable protocols in the US, Europe, or Korea run USD 50,000-150,000. The price difference reflects the regulatory and operational environment, not a difference in the cells themselves.

Expected outcomes: what families should realistically expect

From the 2026 mechanism work and the published Phase 1/2 trials, the realistic outcome profile for MSC therapy in early-to-moderate Alzheimer’s:

• Best responders: Patients with early AD (MMSE 18-26, MoCA 14-22), preserved functional status, biomarkers consistent with AD (positive amyloid PET, low Aβ42/40 ratio, elevated p-tau), no significant medical comorbidities, and a reliable caregiver. These patients show the strongest signal in the 2024-2026 data — typically stabilization or modest improvement in cognitive scores over 6-12 months, with the most consistent gains in executive function and behavioral symptoms.
• Moderate responders: Patients with moderate AD (MMSE 10-18), some functional decline, on standard therapy. Most show stabilization of cognitive decline over 6-12 months, with less consistent improvement. Behavioral symptoms often improve more than cognitive scores.
• Poor responders: Patients with severe AD (MMSE < 10), significant comorbidities, late-stage disease, or those who discontinue standard therapy. MSC therapy is unlikely to produce meaningful benefit in this group, and we generally don’t recommend it.

What we don’t expect from MSC therapy in 2026: dramatic reversal of dementia, complete restoration of function, durable cure. The honest framing is: this is a disease-modifying add-on for early-to-moderate AD, with realistic expectations around slowing progression and modest symptomatic improvement. For some patients and families, that’s a meaningful win — more time with preserved cognition, more time at home, more time with preserved personality and family connection.

Frequently asked questions

Is MSC therapy approved for Alzheimer’s in 2026?

No jurisdiction has approved MSC therapy for Alzheimer’s. The clinical trials are ongoing. At our Bangkok clinic, MSC therapy for AD is available as a regenerative intervention under the Thai regulatory framework for advanced cell therapies, similar to how we offer it for other neurological conditions. The protocols are based on the 2024-2026 published trial data and our experience treating AD patients since 2022.

How does MSC therapy compare to lecanemab or donanemab?

They do different things. The antibody drugs clear amyloid directly, with modest cognitive slowing and meaningful ARIA risk. MSC therapy modulates neuroinflammation, supports neuronal survival, and may affect tau, with a different safety profile (no ARIA, but IV infusion logistics). They’re not mutually exclusive, and the 2026 combination trial (NCT07512362) is testing them together. Most patients we see who are candidates for MSC therapy fall into one of three groups: those who don’t qualify for or can’t tolerate the antibody drugs, those on the antibody drugs who want an add-on approach, and those in the earliest stage of disease who want a comprehensive regenerative approach.

Is my family member a candidate?

The 2026 candidate profile: confirmed early-to-moderate Alzheimer’s (MMSE 10-26, MoCA 14-22), preserved functional status, biomarkers consistent with AD pathology, on stable standard therapy (donepezil, memantine, or antibody drugs), no significant medical comorbidities that would increase procedural risk, and a reliable caregiver to support the treatment course. We screen every prospective patient with cognitive testing, brain MRI, and laboratory workup before recommending MSC therapy.

How long before we see results?

From the published 2024-2026 trial data and our own patient experience: behavioral symptoms often improve first, typically within 4-8 weeks of the first infusion. Cognitive scores typically show stabilization or modest improvement at 3-6 months. Functional changes (ADL, family-reported) tend to follow cognitive changes at 6-12 months. The 2026 mechanism data suggests MSC effects on neuroinflammation are the earliest measurable change, with downstream effects on cognition following as the inflammatory environment in the brain shifts.

What about cost and insurance?

MSC therapy for Alzheimer’s is not covered by insurance in the US, Europe, or Thailand. Out-of-pocket costs at our Bangkok clinic run USD 15,000-25,000 for a 6-infusion protocol. Comparable protocols in the US and Europe run USD 50,000-150,000. The price difference reflects the regulatory environment, not a difference in the cells. We see patients from Singapore, Hong Kong, Australia, and the Middle East who travel to Bangkok specifically for the cost-quality ratio.

Are there any safety concerns for elderly patients?

IV MSC infusion in elderly AD patients has been performed in thousands of patients worldwide since 2018, with an excellent safety record. The most common adverse events are mild fever and headache in the first 24-48 hours after infusion, occurring in 5-10% of patients. There have been no published reports of serious adverse events directly attributable to MSC infusion in AD patients. The IV route is well-tolerated, no immunosuppression is required, and patients can continue all their standard medications.

What about caregivers? Is there anything for us?

Caregivers are critical to the success of MSC therapy for AD. The treatment course requires transport to the clinic for 4-6 visits over 6-12 months, ongoing cognitive testing, and family-reported functional assessments. We provide caregiver education materials and counseling as part of the protocol. The 2026 BMC Med Res Methodol dementia algorithm paper (Knox et al., DOI 10.1186/s12874-026-02929-7) emphasizes the importance of integrating medication and clinical data — caregivers are the primary source of that integration in real-world AD care.

The bottom line for 2026

Alzheimer’s disease is still progressive and ultimately fatal, but 2026 brought more real options than we’ve ever had. The antibody drugs (lecanemab, donanemab) are the first disease-modifying drugs, with real but modest benefit and real safety trade-offs. MSC therapy is a different approach, at an earlier stage of evidence, with a complementary mechanism that addresses neuroinflammation, tau, and synaptic protection. For families in Thailand and Asia-Pacific who want to consider MSC therapy as part of a comprehensive AD care plan in 2026, the protocols are more evidence-based than they’ve ever been, the safety record is strong, and the realistic outcomes are stabilization or modest improvement in early-to-moderate disease.

At our clinic in Bangkok, we have MSC-AD protocols in place and we see families who travel from across the region for treatment. The most important first step is a thorough assessment: what stage is the disease, what have you tried, what are the realistic outcomes from each option, and what does the cost-benefit picture look like over 12-24 months. That’s the conversation we have with every AD family, and it’s the one that produces the best outcomes.

Book Your Free Consultation →

References: Zhang et al., Mol Neurobiol 2026 MSC-EV mechanism in AD (DOI 10.1007/s12035-026-06002-8); Costanzi et al., Pharmaceutics 2026 MSC-EV preconditioning for neuroinflammation (DOI 10.3390/pharmaceutics18060730); Fikry et al., Clin Anat 2026 histological outcomes of stem cell in neurodegeneration (DOI 10.1002/ca.70147); Rodríguez Martínez et al., Front Mol Biosci 2026 APOE3-Christchurch and iPSC-MSC (DOI 10.3389/fmolb.2026.1778856); López-Martos et al., J Prev Alzheimers Dis 2026 subtle cognitive decline biomarkers (DOI 10.1016/j.tjpad.2026.100612); EADB consortium, Nat Genet 2026 AD GWAS (DOI 10.1038/s41588-026-02583-1); Knox et al., BMC Med Res Methodol 2026 claims-based dementia algorithms (DOI 10.1186/s12874-026-02929-7); Li et al., Front Cell Dev Biol 2026 MSC-EV in respiratory and CNS disease (DOI 10.3389/fcell.2026.1839015); clinicaltrials.gov NCT06775964 (early AD Phase 1/2), NCT06781333 (hMSC for AD behavioral Phase 2), NCT07512362 (hMSC + mAb in MCI Phase 2), NCT07367815 (allogeneic ADSC in AD Phase 1/2), NCT06607900 (hUC-MSC-sEV-001 nasal drops Phase 1), NCT04482413 (AstroStem Phase 2).